Innoviva Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform

Corporate ActionProduct / Tech
โดย Insider Monkey·Read original
Summary · why it matters

Innoviva has launched Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral therapies using its proprietary LYNX drug delivery platform. The technology is designed to convert traditional daily oral medicines into extended-release treatments with potential dosing intervals of up to one month. Nortiva Bio operates as a wholly owned subsidiary of Innoviva following the acquisition of the LYNX platform from Lyndra Therapeutics in 2025. Separately, Innoviva Specialty Therapeutics, another subsidiary, announced an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for XACDURO in selected international markets, covering South and Central America, the Caribbean, Russia, and Commonwealth of Independent States countries. Under the deal, Dr. Reddy's will handle development, regulatory processes, and commercialization, while Innoviva Specialty Therapeutics retains rights outside the licensed regions and is eligible for upfront payments, milestone payments, and royalties.

Impact on stocks 2

Aging Population▲ · 1 stocks
Innoviva Inc
INVA
▲ PositiveTechnologyDemandrelevance

Launched Nortiva Bio with proprietary LYNX platform for long-acting oral therapies, a positive technology development.

Health Care▲ · 1 stocks

Off-coverage companies 2

Nortiva Bio, Inc.Private▲ Positive
Technologyrelevance

Nortiva Bio is the newly launched subsidiary focused on the LYNX platform, a positive technology development.

Lyndra Therapeutics, Inc.Private± Mixed
relevance

© 2026 MarketDXNews